Planned Randomized Conversion From Tacrolimus to Sirolimus‐Based Immunosuppressive Regimen in De Novo Kidney Transplant Recipients

@article{Silva2013PlannedRC,
  title={Planned Randomized Conversion From Tacrolimus to Sirolimus‐Based Immunosuppressive Regimen in De Novo Kidney Transplant Recipients},
  author={H. Silva and C. Felipe and V. Garcia and E. D. Neto and M. A. Filho and F. Contieri and D. D. B. M. de Carvalho and J. M. Pestana},
  journal={American Journal of Transplantation},
  year={2013},
  volume={13}
}
Planned conversion from tacrolimus to sirolimus was evaluated in de novo kidney transplant recipients. In this multicenter, randomized, open‐label study, 297 patients were initially treated with tacrolimus, mycophenolate sodium and prednisone. Of the 283 patients reaching 3 months, 97 were converted to sirolimus (SRL), 107 were maintained on tacrolimus (TAC) and 79 were patients receiving TAC without criteria to undergo intervention at month 3 (TACex). The primary objective was to show superior… Expand
Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients
Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
  • R. Haynes, L. Blackwell, +8 authors P. Friend
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2018
Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus
Reviewing 15 years of experience with sirolimus.
Reviewing 15 years of experience with sirolimus
...
1
2
3
4
...

References

SHOWING 1-10 OF 23 REFERENCES
Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study
  • Y. Lebranchu, A. Thierry, +12 authors B. H. de Ligny
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2009
Five‐Year Results of a Randomized Trial Comparing De Novo Sirolimus and Cyclosporine in Renal Transplantation: The Spiesser Study
  • Y. Lebranchu, R. Snanoudj, +11 authors I. Étienne
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2012
Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3‐Year Results From the Randomized ZEUS Study
  • K. Budde, F. Lehner, +12 authors O. Witzke
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2012
The ORION Study: Comparison of Two Sirolimus‐Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients
  • S. Flechner, M. Głyda, +6 authors S. S. Tai
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2011
Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation
  • L. Mjörnstedt, S. Sørensen, +9 authors H. Holdaas
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2012
Mycophenolate Mofetil/Sirolimus Compared to Other Common Immunosuppressive Regimens in Kidney Transplantation
...
1
2
3
...